Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post–Myocardial Infarction Medicare Beneficiaries
2008; Lippincott Williams & Wilkins; Volume: 117; Issue: 10 Linguagem: Inglês
10.1161/circulationaha.107.735605
ISSN1524-4539
AutoresNiteesh K. Choudhry, Amanda R. Patrick, Elliott M. Antman, Jerry Avorn, William H. Shrank,
Tópico(s)Pharmaceutical Economics and Policy
ResumoEffective therapies for the secondary prevention of coronary heart disease-related events are significantly underused, and attempts to improve adherence have often yielded disappointing results. Elimination of patient out-of-pocket costs may be an effective strategy to enhance medication use. We sought to estimate the incremental cost-effectiveness of providing full coverage for aspirin, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and statins (combination pharmacotherapy) to individuals enrolled in the Medicare drug benefit program after acute myocardial infarction.
Referência(s)